Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Stock Down 4.6 %

Aptose Biosciences stock opened at $0.23 on Tuesday. The stock has a 50-day moving average price of $0.27 and a 200 day moving average price of $0.43. The company has a market capitalization of $13.56 million, a price-to-earnings ratio of -0.08 and a beta of 1.07. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.60.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.